Needham initiated coverage on Annexon with a new price target
$ANNX
Biotechnology: Pharmaceutical Preparations
Health Care
Needham initiated coverage of Annexon with a rating of Buy and set a new price target of $37.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/1/2024 | $11.00 | Neutral → Overweight | JP Morgan |
| 12/21/2023 | $4.00 → $6.00 | Neutral → Buy | BofA Securities |
| 10/30/2023 | $11.00 | Overweight | Wells Fargo |
| 5/26/2023 | $8.00 → $3.00 | Buy → Neutral | BofA Securities |
| 5/25/2023 | $19.00 → $9.00 | Overweight → Neutral | JP Morgan |
| 9/16/2022 | $12.00 | Buy | Jefferies |
| 9/9/2022 | $15.00 | Buy | BTIG Research |
| 11/30/2021 | $40.00 | Buy | HC Wainwright & Co. |
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-executive employees received options to purchase 495,000 shares of Annexon common stock. The options carry a ten-year term and
Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor ANX1502 Transitioned to an Enhanced Tablet Formulation; Data in Cold Agglutinin Disease (CAD) Expected in First Quarter 2025 Bolstered Commercial, Medical Affairs and Health Economics Senior Leadership in Preparation for Potential ANX005 Commercialization Robust Balance Sheet with Cash, Cash Equ
BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About AnnexonAnnexon Biosciences (NASDAQ:ANNX) is harnessin
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
SC 13G/A - Annexon, Inc. (0001528115) (Subject)
10-Q - Annexon, Inc. (0001528115) (Filer)
8-K - Annexon, Inc. (0001528115) (Filer)
8-K - Annexon, Inc. (0001528115) (Filer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00
BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously
Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther
BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest
Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 30, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today presented results from the ongoing ARCHER trial in patients with geographic atrophy (GA), underscoring ANX007's potentially distinct neuroprotective mechan
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume AMGN CALL SWEEP BEARISH 07/19/24 $320.00 $27.4K 2.5K 277 LLY CALL TRADE BEARISH 08/16
BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment in the Phase 3 Pivotal Trial of ANX005 in GBS and Phase 1 Data from ANX1502 Oral Small Molecule Company to Provide Updates Across its Portfolio of Complement Therapies During R&D Day in Second Half 2023 Strong Financial Position with Operating Runway into 2025 BRISBANE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company devel